Bristol-myers Squibb

• 

  Pharma Stocks Lift Sensex, Nifty As Dr Reddy's Hits Record High

  The pharmaceutical firm hit an all-time high and was the top boost to the Nifty 50 as it settled a patent litigation with Bristol-Myers Squibb Co over the cancer treatment Revlimid.

• 

  Zydus Inks Pact With Medicines Patent Pool For Hepatitis C Drug

  Drug firm Zydus Cadila has inked a generic manufacturing pact with the Medicines Patent Pool for manufacturing global pharma major Bristol-Myers Squibb's daclatasvir tablets used in the treatment of Hepatitis C.

• 

  Natco Pharma Signs Agreement for Manufacturing, Sale of Hepatitis C Drug

  Natco Pharma has signed a non-exclusive licensing agreement with the Medicines Patent Pool (MPP) and Bristol-Myers Squibb to manufacture and sell generic versions of Daclatasvir, used for the treatment of chronic hepatitis C.

• 

  Dow Rises 117 Points as Rate Hike Worries Ease

  Adding to the day's bullish tone, New York Fed President William Dudley said the US central bank will need to determine whether that jobs report foreshadows a more substantial slowing in the labour market, adding he expects the path of rate hikes to be "relatively shallow."

• Pharma giant Novartis waits nervously on Glivec drug patent verdict today

  Global drugmakers, battered by recent intellectual property decisions in India, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country.

• BDR seeks compulsory licence for cancer drug; offers 95 per cent cheaper generic copy

  Drug firm BDR Pharmaceuticals has applied for a compulsory licence to market generic version of US-based Bristol-Myers Squibb's cancer drug Dasatinib, sold under 'Sprycel' brand, promising to offer the product at price cheaper by over 95 per cent for a month's treatment.

• BDR Pharma seeks license to sell version of a cancer drug

  BDR Pharmaceuticals International Pvt Ltd has applied to the patents office, seeking permission to sell a generic version of Bristol-Myers Squibb Co's cancer drug, Dasatinib, through a so-called compulsory license mechanism, a BDR executive said on Monday.

• Biocon in pact with Bristol-Myers for oral insulin

  Biocon, India's top listed biotech firm, on Friday announced an agreement with Bristol-Myers Squibb for its oral insulin drug IN-105. The deal could potentially earn Biocon hundreds of millions of dollars in royalties. Bristol-Myers Squibb will have the right to exercise an option to obtain an exclusive worldwide license to the program, Biocon said...